Praxis Precision Medicines(NASDAQ) PRAX

Praxis develops medicines for people with brain and nerve disorders. These treatments help fix electrical imbalances in the brain that cause seizures or shaking. The company focuses on helping children and adults who have limited options for their conditions.

What Praxis Is Building

• Small Molecule Platform: Orally available pills designed to balance brain activity; includes ulixacaltamide for shaking and vormatrigine for common seizures.
• Antisense Oligonucleotide Platform: Targeted gene therapy that works like a genetic dimmer switch to turn specific brain signals up or down.
• Movement Disorder Treatments: Specialized medicine to help people who suffer from involuntary rhythmic movements in their hands or head.
• Epilepsy Programs: Precision therapies for rare genetic seizures in children and more common seizure types in adults.

Strategic Partnerships and Progress

• Entered a license agreement with Tenacia Biotechnology to develop and sell ulixacaltamide in the China region.
• Collaborated with Ionis Pharmaceuticals to discover and develop gene-based therapies for pediatric epilepsy.
• In-licensed a specific epilepsy program, PRAX-020, to the pharmaceutical company UCB for further development.
• Partnered with The Florey Institute to research three new genetic treatments for brain disorders.
• Established a license agreement with RogCon to focus on treatments for SCN2A-related brain conditions.

What Makes the Business Unique

Praxis uses two distinct technology systems to create both traditional pills and advanced genetic treatments. This approach allows the company to target the specific biological cause of a disease rather than just treating the symptoms.

The Recent Financial Record

• Net income was a loss of $88.9 million in Q4 2025, widening 51.5% from the previous year.
• Market capitalization reached $6.6 billion in Q4 2025, a 331% increase year-over-year.
• Operating cash flow was negative $77.3 million in Q4 2025, compared to negative $56.1 million in Q4 2024.
• Revenue fell to $0 in Q4 2025, down from $7.5 million in Q4 2024.

Bottom Line

Praxis has transitioned from an early research firm into a late-stage clinical company with multiple products nearing regulatory review. Its focus on genetic precision allows it to develop specialized therapies for both rare pediatric conditions and large adult markets.